Login to Your Account

In The Clinic NEWS

AMSTERDAM – New data on Albireo Pharma Inc.'s A-4250, an ileal bile acid transport inhibitor, has shown its capacity to reduce high levels of serum bile acids, which are often associated with severe itching, or pruritus, and liver damage in children with the rare cholestatic liver disease PFIC.

AMSTERDAM – Bristol-Myers Squibb Co.'s lead NASH candidate, BMS-986036, significantly reduced liver fat vs. placebo, meeting the primary endpoint of a phase II trial.

AMSTERDAM – NGM Biopharmaceuticals Inc. honed in on the liver de-fatting feats of its lead candidate, NGM282, during a presentation at the International Liver Conference.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: